Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
Date:5/5/2009

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present a corporate overview at the following investment conferences:

  • Bank of America Merrill Lynch 2009 Healthcare Conference at the Palace Hotel in New York City on Tuesday, May 12, 2009 at 2:40pm Eastern Time (11:40am Pacific Time)
  • Deutsche Bank's 34th Annual Health Care Conference at the InterContinental Hotel in Boston on Tuesday, May 19, 2009 at 1:55pm Eastern Time (10:55am Pacific Time)

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com. To access the presentations, click on the Investor Relations tab the link entitled "Events and Presentations" on the left side of the screen. A replay of each webcast will available approximately one hour after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCal...dthatRandyScott,GenomicHealth,sExecutiveChairman,w...ferenceinNewYorkCityonTuesday,December1,2009at10:0...vedwebcastofthepresentation,visittheInvestorRelati...or.genomichealth.com .Pleaseconnecttothewebsiteatl...
(Date:11/24/2009)... Chemical Abstracts Service ...reports that China,s patent office is now the worl...ons in chemistry. China trailed Japan,s patent off...(WIPO), and the United States Patent and Trademark... the USPTO in 2005, WIPO in 2006, and exceeded Jap...
(Date:11/23/2009)...HAMPAIGN, Ill. You can think of it as origami ve...sity of Illinois have developed a technique for fa...licon structures from thin films by coupling photo...apillary interactions. , The films, only a few mi...not possible with thicker pieces of the same mater...
(Date:11/23/2009)..., INCLINEVILLAGE,Nev.,Nov.23/PRNewswire-FirstCa...ouncedthatNASDAQhasestablishedNovember27,2009asthe...tockholdersresultingfromthesecuritizationtransacti...nDecember15,2009toallstockholdersofrecordonthereco...rshareamountofthedividendat$1.67pershareofcommonst...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...., Jan. 13 Nektar Therapeutics,(Nasdaq: NKTR ) ... 2 clinical,trial of NKTR-102 in platinum-resistan...been obtained and dosing will begin shortly in two...evaluate NKTR-102 versus irinotecan in,second-line...ation, and a,Phase 2 study in metastatic breast ca...
.... 13 Burnham Institute for Medical Research (Burn...greement with Johnson & Johnson Pharmaceutical...he agreement is Burnham,s first broad-based partne...der this multi-year agreement, Burnham will provid...screening technologies to investigate certain drug...
...., Jan. 13 Neurobiological,Technologies, Inc. (Na...owing a,detailed analysis of the recent interim re...any has decided not to develop Viprinex further fo... was recently studied in a,clinical trial to deter...,outcome when given within six hours of a stroke, ...
Other Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2Neurobiological Technologies Announces Suspension of Viprinex Development 2Neurobiological Technologies Announces Suspension of Viprinex Development 3
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
(Date:11/25/2009)...eath Research Laboratory in the University of Haif...estigious Johnson & Johnson Focused Funding grant ... damage in Parkinson,s disease. The award, which i...novation and excellence in science, was announced ...th at an event at the Hyatt Regency Hotel in New J...
(Date:11/25/2009)...fessors recently received funding from the Nationa...neficial to understanding the environment. The thr...d, assistant professor in the Department of Biolog...eparate research projects. , His first project, ...nd Functions from the Leaf to the Landscape," will...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Rigel to Present at Jefferies Healthcare Conference 48415 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 1Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 2
... subjects to operate a robot-controlled joystick, ...er the brain "learns" to control certain muscle mo...son over the long haul. The results, the investiga...r people who have lost motor abilities to brain in... the May 23 issue of PLoS Biology, the researchers...
...archers have found a group of cells in the intesti...lls, cells that help fight infection. , The resear...journal Immunity, released today. , "This connect... will help in studying and developing treatments f...m," said Stephen McSorley, Ph.D., professor of med...
...t four factors, researchers have successfully indu...or adult mice to behave like embryonic stem cells....ediate early publication of the journal Cell, publ...rchers designate "induced pluripotent stem cells" ...haracteristics typical of embryonic stem cells, th...
Other Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3With few factors, adult cells take on character of embryonic stem cells 2
Mouse Anti-Mouse Qa-2 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone 695H1-9-9 from BioLegend
27-mer duplex from B-Bridge International
Propidium Iodide Buffer from BioLegend
Luminex 100 Instrument System from Upstate
Biology Products: